Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Neurol Sci ; 41(2): 451-455, 2020 Feb.
Article in English | MEDLINE | ID: mdl-31506829

ABSTRACT

Alzheimer's disease (AD) is the most incident neurodegenerative disorder, characterized by accumulation of extracellular amyloid-ß (Aß), intracellular neurofibrillary tangles, and cognitive impairment. The current available treatments are mainly based on the use of reversible acetylcholinesterase (AChE) inhibitors, which only ameliorate the cognitive deficits. However, it is important to develop disease-modifying drugs with neuroprotective effects in order to hamper the progression of the disease. Here, we describe the effect of four promising new drugs with additional protective characteristics on AD-associated memory changes. C57Bl/6 mice treated with the compounds received an intra-hippocampal injection of Aß1-40 and were submitted to the novel object recognition test, to evaluate memory recovery. All the compounds prevented memory loss. Compounds PQM-56 (4c) and PQM-67 (4g) showed the best profile of memory recovery, representing potential drug candidates for AD treatment.


Subject(s)
Alzheimer Disease/drug therapy , Cholinesterase Inhibitors/pharmacology , Memory Disorders/drug therapy , Memory/drug effects , Amyloid beta-Peptides/metabolism , Animals , Cognition Disorders/drug therapy , Disease Models, Animal , Memory Disorders/chemically induced , Mice, Inbred C57BL , Neuroprotective Agents/therapeutic use , Peptide Fragments/pharmacology
2.
Neurosci Lett ; 711: 134408, 2019 10 15.
Article in English | MEDLINE | ID: mdl-31374324

ABSTRACT

Heavy episodic drinking or binge drinking during adolescence may elicit serious neurotoxic consequences in cerebral areas (e.g., the prefrontal cortex, i.e., PFC) and the hippocampus, delay the maturation of the brain and increase the probability of drug abuse and dependence. The endocannabinoid system plays an important role in neuroprotection by reducing oxidative stress and neuroinflammation. In the present study, we aimed to investigate whether URB597, an inhibitor of the metabolic enzyme of the endocannabinoid anandamide (AEA), altered the effects of acute and chronic alcohol administration beginning during rat adolescence on recognition memory, neuroinflammation and brain-derived neurotrophic factor (BDNF) levels. The animals received intraperitoneal injections of URB597 (0.3 mg/Kg) or vehicle followed by the oral administration of ethanol (3 or 6 g/Kg) or distilled water for 3 consecutive days in one week (acute binging) or over 4 weeks (chronic binging). The groups were submitted to the novel object recognition task, and their PFCs and hippocampi were removed for analyses of the cytokine and BDNF levels. URB597 potentiated long-term memory after the 3 mg/Kg acute alcohol administration. The chronic binge alcohol administration increased the interferon (IFN)-γ and tumor necrosis factor (TNF)-α levels in the PFC and hippocampus and the interleukin (IL)-10 and BDNF levels in the PFC, and these effects were prevented by URB597. Our results indicate that the neuromodulation facilitated by AEA can reduce the neuroimmune response induced by the chronic administration of alcohol beginning in adolescence in rats.


Subject(s)
Benzamides/pharmacology , Binge Drinking , Brain/drug effects , Carbamates/pharmacology , Aging , Amidohydrolases/antagonists & inhibitors , Animals , Brain/metabolism , Brain-Derived Neurotrophic Factor/drug effects , Brain-Derived Neurotrophic Factor/metabolism , Cytokines/drug effects , Cytokines/metabolism , Male , Rats , Rats, Wistar
3.
Epilepsia ; 58(12): e162-e166, 2017 12.
Article in English | MEDLINE | ID: mdl-29105060

ABSTRACT

The endocannabinoid system has gained attention as an important modulator of activity in the central nervous system. Initial studies focused on cannabinoid receptor 1 (CB1), which is widely expressed in the brain, but recent work also implicates cannabinoid receptor 2 (CB2) in modulating neuronal activity. Both receptors are capable of reducing neuronal activity, generating interest in cannabinoid receptor agonists as potential anticonvulsants. CB1 (Cnr1) and CB2 (Cnr2) single-knockout mice have been generated, with the former showing heightened seizure sensitivity, but not overt seizures. Given overlapping and complementary functions of CB1 and CB2 receptors, we queried whether double-knockout mice would show an exacerbated neurological phenotype. Strikingly, 30% of double-knockout mice exhibited provoked behavioral seizures, and 80% were found to be epileptic following 24/7 video-electroencephalographic monitoring. Single-knockout animals did not exhibit seizures. These findings highlight the importance of the endocannabinoid system for maintaining network stability.


Subject(s)
Epilepsy/genetics , Receptor, Cannabinoid, CB1/genetics , Receptor, Cannabinoid, CB2/genetics , Animals , Behavior, Animal , Electroencephalography , Epilepsy/etiology , Handling, Psychological , Mice , Mice, Inbred C57BL , Mice, Knockout , Nerve Net/physiopathology , Phenotype , Seizures/etiology , Seizures/genetics , Seizures/psychology
4.
Epilepsy Behav ; 75: 29-35, 2017 10.
Article in English | MEDLINE | ID: mdl-28821005

ABSTRACT

Cannabidiol (CBD), the main nonpsychotomimetic compound from Cannabis sativa, inhibits experimental seizures in animal models and alleviates certain types of intractable epilepsies in patients. Its pharmacological profile, however, is still uncertain. Here we tested the hypothesis that CBD anticonvulsant mechanisms are prevented by cannabinoid (CB1 and CB2) and vanilloid (TRPV1) receptor blockers. We also investigated its effects on electroencephalographic (EEG) activity and hippocampal cytokines in the pentylenetetrazole (PTZ) model. Pretreatment with CBD (60mg/kg) attenuated seizures induced by intraperitoneal, subcutaneous, and intravenous PTZ administration in mice. The effects were reversed by CB1, CB2, and TRPV1 selective antagonists (AM251, AM630, and SB366791, respectively). Additionally, CBD delayed seizure sensitization resulting from repeated PTZ administration (kindling). This cannabinoid also prevented PTZ-induced EEG activity and interleukin-6 increase in prefrontal cortex. In conclusion, the robust anticonvulsant effects of CBD may result from multiple pharmacological mechanisms, including facilitation of endocannabinoid signaling and TRPV1 mechanisms. These findings advance our understanding on CBD inhibition of seizures, EEG activity, and cytokine actions, with potential implications for the development of new treatments for certain epileptic syndromes.


Subject(s)
Anticonvulsants/pharmacology , Brain , Cannabidiol/pharmacology , Cytokines/metabolism , Seizures/prevention & control , Animals , Brain/drug effects , Brain/metabolism , Brain/physiopathology , Convulsants/pharmacology , Disease Models, Animal , Male , Mice , Pentylenetetrazole/pharmacology , Seizures/chemically induced , Seizures/metabolism , Seizures/physiopathology
5.
J Psychopharmacol ; 31(6): 750-756, 2017 06.
Article in English | MEDLINE | ID: mdl-28583049

ABSTRACT

Anandamide, an endocannabinoid, inhibits aversive responses by activating the CB1 cannabinoid receptor. At high concentrations, however, anandamide may exert pro-aversive activities mediated by the transient receptor potential vanilloid type-1 channel (TRPV1). Accordingly, N-arachidonoyl-serotonin (AA-5-HT), a dual blocker of the anandamide-hydrolysing enzyme fatty acid amide hydrolase (FAAH) and the TRPV1 channel, induces anxiolytic-like effects. Here we tested the hypothesis that AA-5-HT inhibits the expression of contextual fear conditioning by facilitating CB1 receptor signalling in the dorsal hippocampus of mice. Intraperitoneal injection of AA-5-HT (0.1, 0.3, 1 mg/kg) inhibited the retrieval of contextual fear memory (freezing response). The effect of AA-5-HT (0.3 mg/kg) was prevented by systemic injection of the CB1 receptor antagonist, AM251 (1.0 mg/kg), and mimicked by simultaneous FAAH inhibition (URB597, 0.3 mg/kg) and TRPV1 blockage (SB366791, 1 mg/kg). Injection of AA-5-HT (0.125, 0.25, 0.5 nmol) into the dorsal hippocampus also reduced freezing. Finally, the effect of systemic AA-5-HT (0.3 mg/kg) was prevented by intra-hippocampal injection of AM251 (1 nmol). In conclusion, dual FAAH and TRPV1 blockage inhibits contextual fear memory by facilitating anandamide-induced CB1 receptor activation in the dorsal hippocampus. This approach may lead to new pharmacological treatments for traumatic memories and related psychiatric disorders.


Subject(s)
Amidohydrolases/antagonists & inhibitors , Arachidonic Acids/pharmacology , Fear/drug effects , Hippocampus/drug effects , Memory/drug effects , Receptor, Cannabinoid, CB1/metabolism , Serotonin/analogs & derivatives , TRPV Cation Channels/antagonists & inhibitors , Animals , Endocannabinoids/pharmacology , Hippocampus/metabolism , Male , Mice , Polyunsaturated Alkamides/pharmacology , Serotonin/pharmacology
6.
Nat Prod Res ; 26(4): 331-43, 2012.
Article in English | MEDLINE | ID: mdl-21432718

ABSTRACT

Several species of Senna are well known for their therapeutic properties, being used in folk medicine to treat throat inflammation and constipation. In this regard, the anti-inflammatory, laxative and intestinal motility effects of different extracts of Senna macranthera (Colladon) H. Irwin and Barneby leaves were determined. The hexane extract significantly reduced carrageenan-induced paw oedema in rats in a manner similar to that of sodium diclofenac. A laxative effect was observed for the methanolic and hexane extracts comparative to the standard drug bisacodyl; however, only the hexane extract increased the intestinal motility in the studied period. Moreover, the extracts were evaluated for their antioxidant activity and the ethyl acetate extract presented a pronounced activity comparable to the standard rutin. Phytochemical screening was also performed and phenolic compounds like flavonoids, tannins and coumarins were observed in all extracts except for the hexane extract, which instead presented anthrones, triterpenes and steroids in its composition. The HPLC profile showed the presence of the anthraquinone emodine in all tested extracts.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Gastrointestinal Motility/drug effects , Laxatives/pharmacology , Plant Extracts/pharmacology , Senna Plant/chemistry , Animals , Anti-Inflammatory Agents/chemistry , Antioxidants/chemistry , Antioxidants/pharmacology , Carrageenan/toxicity , Chromatography, High Pressure Liquid , Coumarins/isolation & purification , Drug Evaluation, Preclinical/methods , Edema/chemically induced , Edema/drug therapy , Flavonoids/analysis , Flavonoids/chemistry , Flavonoids/isolation & purification , Laxatives/chemistry , Male , Plant Extracts/chemistry , Plant Leaves/chemistry , Plants, Medicinal/chemistry , Rats , Rats, Wistar , Tannins/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL
...